Pharmaceuticals, Biotechnology and Life Sciences
Kayentis, a global provider of eCOA and Decentralized Clinical Trial solutions, has announces the launch of a fully integrated patient-centric…
ONK Therapeutics has appointed Allan Reine as independent Non-Executive Director to its Board.
Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany.
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
ReNeuron Group plc (AIM: RENE), a UK-based Stem Cell and Exosomes zechnologies company, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
Leica Microsystems has introduced the new Coral Cryo workflow solution. The workflow solution enables researchers to increase their success rate…
Bristol Myers Squibb has announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session, taking place in Washington, DC, and virtually, from April 2-4, 2022.
Moderna has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.